Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 + Paclitaxel/Carboplatin in Advanced NSCLC
NCT02182232Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2005
- Primary completion
- May 2007
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Incidence and intensity of adverse events and Maximum tolerated dose. Started Jun 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02182232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182232.